A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

By sjmartinez • February 7, 2024

Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, Shaw K, van Besien K, Gomez-Arteaga A, Stevens D, Ortuzar W, Michelet X, Smith R, Moskowitz D, Masakayan R, Yigit B, Boi S, Soh KT, Chamberland J, Song X, Qin Y, Mishchenko I, Kirby M, Nasonenko V, Buffa A, Buell JS, Chand D, van Dijk M, Stebbing J, Exley MA. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nat Commun. 2024 Feb 6;15(1):974. doi: 10.1038/s41467-024-44905-z. PMID: 38321023.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Response to Baroukhian et al., “Pemphigus following herpes simplex infection: A global comprehensive cohort study”

Curman P, Ngo BT, Hernandez G, Kridin K, Ludwig RJ, Kasperkiewicz M. Response to Baroukhian et al., "Pemphigus following herpes simplex infection: A global comprehensive[...]

PPARγ-dependent remodeling of translational machinery in adipose progenitors is impaired in obesity

De Siqueira MK, Li G, Zhao Y, Wang S, Ahn IS, Tamboline M, Hildreth AD, Larios J, Schcolnik-Cabrera A, Nouhi Z, Zhang Z, Tol MJ,[...]

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF,[...]